<DOC>
	<DOCNO>NCT02959606</DOCNO>
	<brief_summary>After endovascular treatment ( EVT ) peripheral artery disease ( PAD ) , dual antiplatelet therapy ( DAAT ) aspirin ( ASA ) clopidogrel currently drug choice prevent occlusion . Anplone SRÂ® , controlled-released Sarpogrelate hydrochloride , introduce anti-platelet agent drug PAD . The aim study compare efficacy safety Anplone + aspirin clopidogrel + aspirin patient underwent EVT femoro-popliteal occlusive disease .</brief_summary>
	<brief_title>SAFE ( Sarpogrelate Anplone Femoro-popliteal Artery Intervention Efficacy ) Study</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>1 . Adult , &gt; 18 year old 2 . Angiographicallyconfirmed significant femoropopliteal ( FP ) stenosis occlusion atherosclerosis 3 . Successful FP intervention ; residual stenosis &lt; 30 % 4 . Without significant residual inflow disease ; Intact iliac artery inflow ( without intervention iliac knee artery ) 5. patent outflow status ; least 1 arterial runoff knee arteries 6 . All kind fempop intervention include POBA , stent , DCB , DES TASC A~ D 1 . At risk hemorrhage , bleed tendency thrombophilia 2 . Acute limb ischemia / inflammatory arterial disease 3 . Contraindication allergic ASA , clopidogrel , Anplone 4 . Medication warfarin 5 . Pregnancy , hepatic dysfunction , thrombocytopenia 6 . Previous FP bypass intervention 7 . Impossible stop clopidogrel EVT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>